Seth P Lerner
Overview
Explore the profile of Seth P Lerner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
274
Citations
9360
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Gulati S, Tangen C, Ryan C, Vaishampayan U, Shuch B, Barata P, et al.
JAMA Netw Open
. 2024 Aug;
7(8):e2425288.
PMID: 39106067
Importance: Clinical trial data on adjuvant therapy in patients with non-clear cell renal cell carcinoma (RCC) are scant. Objective: To evaluate the effect of adjuvant everolimus after nephrectomy on recurrence-free...
12.
Tripathi A, Tangen C, Plets M, Li X, Tretiakova M, Humphrey P, et al.
BJU Int
. 2024 Jul;
134(4):596-601.
PMID: 39014969
Objective: To evaluate the clinical significance of subtyping (type 1 vs 2) of papillary renal cell carcinoma (PRCC) in patients treated with targeted therapy, as well as the concordance, sensitivity...
13.
Plimack E, Tangen C, Plets M, Kokate R, Xiu J, Nabhan C, et al.
Eur Urol
. 2024 Jul;
86(4):297-300.
PMID: 39003201
We previously reported that tumors harboring any one of four gene mutations (ATM, RB1, FANCC, or ERCC2) were likely to respond to neoadjuvant cisplatin-based chemotherapy (NAC), resulting in cancer-free surgical...
14.
Mehr J, Bates J, Lerner S
Bladder Cancer
. 2024 Jul;
9(1):41-48.
PMID: 38994480
Background: One of the best predictors of positive outcomes in bladder cancer (BC) is pT0 following radical cystectomy (RC). Discordance between clinical and pathologic staging affects decision-making in patients with...
15.
McConkey D, Baumann B, Greenberg S, DeGraff D, Delacroix S, Efstathiou J, et al.
Bladder Cancer
. 2024 Jul;
10(1):1-8.
PMID: 38993535
No abstract available.
16.
Kamat A, Lobo N, Lerner S, Li R, Matulay J, Palou J, et al.
Bladder Cancer
. 2024 Jul;
8(2):113-117.
PMID: 38993360
When it comes to the treatment of patients with non-muscle-invasive bladder cancer (NMIBC) with intravesical bacillus Calmette-Guérin (BCG), two questions must be considered: 1) what dose to give, and 2)...
17.
Meeks J, Sjodahl G, Lerner S, Das A, McConkey D, Black P
Bladder Cancer
. 2024 Jul;
7(1):1-11.
PMID: 38993221
Background: Bladder cancers have high total mutation burdens resulting in genomic diversity and intra- and inter-tumor heterogeneity that may impact the diversity of gene expression, biologic aggressiveness, and potentially response...
18.
Chang E, Hahn N, Lerner S, Fallah J, Agrawal S, Kamat A, et al.
Bladder Cancer
. 2024 Jul;
9(3):271-286.
PMID: 38993184
Background: Despite recent drug development for non-muscle invasive bladder cancer (NMIBC), few therapies have been approved by the US Food and Drug Administration (FDA), and there remains an unmet clinical...
19.
Gebrael G, Jo Y, Swami U, Plets M, Hage Chehade C, Narang A, et al.
JAMA Netw Open
. 2024 Jul;
7(7):e2419966.
PMID: 38980676
Importance: The presence of bone pain is significantly associated with worse overall survival (OS) in patients with castration-resistant prostate cancer. However, there are few data regarding bone pain and survival...
20.
Jin F, Thaiparambil J, Donepudi S, Vantaku V, Piyarathna D, Maity S, et al.
Cancer Prev Res (Phila)
. 2024 Jun;
17(6):281.
PMID: 38831722
No abstract available.